Chronic Pain Treatment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031F

Neuropathic Pain is the fastest growing sector, North America is the largest market

The Global Chronic Pain Treatment Market is projected to expand significantly, rising from USD 86.23 Billion in 2025 to USD 136.53 Billion by 2031, demonstrating a Compound Annual Growth Rate (CAGR) of 7.96%. This market includes a range of solutions, from medications and medical devices to various therapies, all aimed at managing pain that lasts over three months. Key factors propelling this growth include a globally aging population and an increasing prevalence of chronic conditions like arthritis, neuropathy, and cancer. The immense demand for these treatments is highlighted by the International Association for the Study of Pain, which reported in 2024 that more than 20% of the world's population suffered from chronic pain, emphasizing the urgent need for effective and readily available therapeutic options to alleviate this widespread health crisis.

Despite this growth potential, the market faces considerable obstacles, primarily due to strict regulations imposed on opioid analgesics, driven by global concerns about abuse and addiction. Increased oversight has resulted in more rigorous prescription guidelines, which in turn cause reluctance among healthcare providers and hinder patient access to established treatments. Consequently, manufacturers encounter significant challenges in navigating complex regulatory frameworks as they strive to develop non-addictive alternatives. This situation complicates development timelines and limits the swift expansion of the chronic pain treatment landscape.

Market Drivers

A major catalyst for market expansion is the escalating prevalence of chronic health conditions, largely influenced by an aging global population and a rise in lifestyle-related disorders. The growing number of elderly individuals leads to a higher incidence of degenerative diseases, such as osteoarthritis and diabetic neuropathy, ensuring a continuous demand for therapeutic solutions. This expanding patient demographic is supported by data from the Centers for Disease Control and Prevention (CDC), which reported in November 2024 that 24.3% of U.S. adults experienced chronic pain in 2023. Such high incidence also imposes a substantial economic burden, estimated at $725 billion annually in the U.S. for chronic pain management in 2024, according to the International Society for Pharmacoeconomics and Outcomes Research (ISPOR), thereby encouraging the adoption of effective treatments.

Simultaneously, technological advancements in neurostimulation and various pain management devices are transforming the market by offering advanced non-opioid options. Companies are actively bringing to market next-generation spinal cord stimulation (SCS) systems, which are designed to provide precise and individualized pain relief while minimizing side effects.

These innovative solutions are quickly gaining favor among healthcare professionals, especially as they contend with stricter opioid prescription regulations. The significant commercial impact of these technological developments is evident in recent industry figures, with Boston Scientific reporting in October 2024 that its Neuromodulation segment achieved $268 million in net sales, reflecting a 17.0% year-over-year growth in the third quarter of 2024. This strong performance underscores a growing preference for device-based interventions in addressing intractable pain.

Market Challenges

The Global Chronic Pain Treatment Market encounters significant hurdles primarily due to the strict regulatory framework surrounding opioid analgesics. This intensified oversight, stemming from worldwide concerns about abuse and addiction, has fundamentally reshaped how pain management prescriptions are issued. Healthcare providers now operate under more restrictive guidelines that discourage traditional opioid therapies, resulting in considerable reluctance to prescribe these treatments, even for valid chronic conditions. Such regulatory pressure directly impedes patient access and effectively shrinks the market for a substantial portion of existing pharmacotherapies. Consequently, the market faces a bottleneck where the reduction in opioid use is not yet balanced by the uptake of non-opioid alternatives, leading to stagnation in overall revenue growth.

The extent of these limitations is clearly demonstrated by recent industry data, which indicates a sharp decline in the availability of these medications. For instance, the American Medical Association reported in 2024 that opioid prescriptions nationwide had fallen by nearly 52% since 2012. This dramatic decrease illustrates how regulatory actions are actively diminishing the commercial presence of established pain treatments. In response, manufacturers are compelled to navigate intricate compliance procedures while urgently developing new therapeutic options to bridge this gap, a process that invariably slows the introduction of novel products and restricts the rapid expansion of the wider treatment market.

Market Trends

A significant market trend is the rapid embrace of non-opioid pharmacological therapies, driven by manufacturers' success in overcoming previous hurdles to introduce innovative, non-addictive treatments for long-term conditions. This development addresses the crucial demand for safer pain relief by introducing new drug classes, such as sodium channel inhibitors and sublingual formulations, which effectively circumvent the risks associated with conventional opioids. A prime example of this transformative shift is the regulatory approval of Tonmya (TNX-102 SL) by the U.S. FDA in August 2025, as reported by HCPLive in January 2026. This marked the first new pharmaceutical therapy for fibromyalgia in over 15 years, validating the industry's strategic focus on developing effective, non-habit-forming pharmacological options and thereby broadening the treatment landscape for millions suffering from intractable chronic pain.

Simultaneously, the integration of digital therapeutics and remote patient monitoring is fundamentally transforming healthcare delivery by offering continuous, home-based management for individuals with musculoskeletal and chronic pain. These advanced platforms utilize wearable sensors and artificial intelligence to guide physical therapy, monitor adherence, and customize interventions in real-time, consequently reducing the necessity for frequent in-person clinic visits.

The commercial viability and swift adoption of these digital solutions are evident in the robust financial performance of leading innovators in this sector who are effectively monetizing these virtual care models. According to MobiHealthNews in August 2025, Hinge Health reported a 55% year-over-year revenue increase in the second quarter of 2025, reaching $139.1 million. This surge in adoption clearly demonstrates that healthcare providers and payers are increasingly recognizing digital modalities as vital, scalable elements of contemporary chronic pain treatment protocols.

Key Market Players

• Pfizer Inc
• Abbott Laboratories
• Eli Lilly and Company
• Novartis AG
• Johnson & Johnson
• Sanofi SA
• Teva Pharmaceutical Industries Ltd
• Baxter International
• Merck & Co. Inc
• Boston Scientific Corporation

Report Scope

In this report, the Global Chronic Pain Treatment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Chronic Pain Treatment Market, by Indication:

• Neuropathic Pain
• Analgesic Infusion
• Ablation

Chronic Pain Treatment Market, by Product Type:

• Drugs
• Devices

Chronic Pain Treatment Market, by Distribution Channel:

• Hospital & Clinics
• Ambulatory Centers
• Others

Chronic Pain Treatment Market, by Region:

• North America
• Europe
• Asia Pacific
• South America
• Middle East & Africa

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Chronic Pain Treatment Market.

Available Customizations:

With the given market data, the publisher offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

This product will be delivered within 1-3 business days.